Research window: 16–23 October 2026.
Three human trials offer useful findings: a negative cholesterol result, tentative mushroom-related mood findings and a maternal supplement study with longer follow-up. None demonstrates lifespan extension.
Does this change current advice?
These studies do not establish a new reason for routine supplementation. Their value lies in testing specific claims and showing where promising findings remain uncertain.
1. Plant sterols: no cholesterol benefit in a small obesity trial
Read the plant-sterol trial abstract and access the paper — 16 October 2026, American Journal of Clinical Nutrition. DOI: 10.1016/j.ajcnut.2026.101588.
Twenty-three participants with overweight or obesity and mild hypercholesterolaemia received 2 g/day plant sterols and placebo for eight weeks each, separated by six weeks.
The primary outcome, LDL cholesterol, did not differ between treatments (p=0.632). Other cardiometabolic and body-composition outcomes showed no significant benefit after correction for multiple testing.
Why it matters: This directly tests cholesterol-lowering expectations in this population. It provides no support for weight-loss claims.
Practical takeaway and limitations: One small trial cannot settle effectiveness across all populations. LDL is a risk marker; cardiovascular events were not assessed. The trial was powered for LDL, so secondary findings remain exploratory. Do not use this result alone to change prescribed lipid treatment.
Disclosures: Reported support included Spanish public research funding.
Worth reading in full: Top read, for the primary null result and handling of exploratory outcomes.
2. Lion’s mane and Reishi: promising comparisons need caution
Read the mushroom mood and wellbeing trial — 20 October 2026, Frontiers in Nutrition.
A double-blind trial randomised 84 young women with self-reported stress or anxiety to Lion’s mane, a Lion’s mane–Reishi blend or placebo for 28 days.
The blend produced lower primary anxiety scores than Lion’s mane alone. That comparison does not establish superiority to placebo. Secondary anxiety and stress findings did not remain significant after correction across secondary outcomes; fatigue and self-esteem showed no treatment effect.
Why it matters: Controlled human evidence helps scrutinise increasingly popular mushroom claims.
Practical takeaway and limitations: These preliminary results do not establish treatment for an anxiety disorder. Recruitment fell short of the intended sample, and follow-up was short. Adverse-event frequency did not differ significantly, which does not establish long-term safety.
Funding and disclosures: Northumbria University funded the study; Sempera Organics supplied products. The authors reported no commercial or financial conflicts.
Worth reading in full: Second priority, particularly to distinguish active-treatment comparisons from placebo evidence.
3. Maternal synbiotics: infant-weight signal, uncertain clinical meaning
Read the maternal synbiotic trial — 19 October 2026, BMC Pediatrics. Peer-reviewed accepted manuscript, subject to further editing.
Ninety-six lactating women with exclusively breastfed term infants received a synbiotic or placebo for 28 days. Infant growth was followed to 12 months. Weight-for-age trajectories favoured supplementation at 12 months (adjusted difference 0.528 z-score units; 95% CI 0.093–0.963). Length and head-circumference trajectories did not differ.
Why it matters: The study examines longer-term growth following a brief maternal intervention.
Practical takeaway and limitations: Higher weight alone does not establish healthier development. Retrospective registration and uncertain clinical significance limit confidence. These results do not establish a routine maternal or infant supplementation recommendation.
Funding and disclosures: Shahid Sadoughi University of Medical Sciences support; no competing interests declared.
Worth reading in full: Optional, for infant-nutrition specialists assessing applicability.
Educational research summary, not individual treatment advice. Findings apply to the populations and formulations studied. Source links checked: 23 October 2026. This is a focused roundup, not a systematic review.